Navigation Links
Sunesis Announces New Data on Voreloxin for Acute Myeloid Leukemia and Ovarian Cancer Will Be Presented at ASCO
Date:5/26/2009

-- Conference Call Scheduled for Monday June 1 at 1:00 PM ET to Discuss ASCO Data Presentations --

SOUTH SAN FRANCISCO, Calif., May 26 /PRNewswire-FirstCall/ -- Sunesis Pharmaceuticals, Inc. (Nasdaq: SNSS), a biopharmaceutical company focused on the development and commercialization of new oncology therapeutics, today announced that updated interim data from the Company's ongoing Phase 2 clinical trials in frontline acute myeloid leukemia (AML) and platinum-resistant ovarian cancer and its Phase 1b/2 clinical trial in relapsed/refractory AML will be presented during the American Society of Clinical Oncology (ASCO) 2009 Annual Meeting in Orlando, Florida, which begins May 29, 2009. Following are the details on each of these data presentations.

               Saturday May 30, 8:00AM to 12:00PM (poster presentation)
               Abstract #7048
               Title: "A phase II study of voreloxin as single agent therapy
               for elderly patients (pts) with newly diagnosed acute myeloid
               leukemia (AML)."
               Location: Level 2, West Hall C
               Board #M2

               Sunday May 31, 2:00PM to 6:00PM (poster presentation)
               Abstract #5559
               Title: "A phase II trial of voreloxin in women with
               platinum-resistant ovarian cancer."
               Location: Level 2, West Hall C
               Board #M18

               Monday June 1, 10:30AM (oral presentation)
               Abstract #7005
               Title: "Phase Ib/II pharmacokinetic/pharmacodynamic (PK/PD)
               study of combination voreloxin and cytarabine in relapsed or
               refractory AML patients."
               Location: Level 2, West Hall F1

Additionally at the ASCO 2009 Annual Meeting, Sunesis will be presenting clinical
'/>"/>

SOURCE Sunesis Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4

Related medicine news :

1. Major Pharma Clinical Case Studies From Amgen, AstraZeneca, GSK, Intermune, Cephalon Inc, Sunesis Pharmaceuticals and Dartmouth Medical School During Fall Clinical Focused Programs
2. Sunesis Pharmaceuticals Reports New Option Grants Under NASDAQ Marketplace Rule 4350
3. Sunesis Pharmaceuticals SNS-595 Shows Clinical Activity in Patients With Relapsed or Refractory Acute Leukemias; Data Presented in Oral Session at 49th Annual Meeting of the American Society of Hematology
4. Sunesis Pharmaceuticals to Present at Healthcare Investor Conferences in March
5. Sunesis Pharmaceuticals Presents Nonclinical Data on SNS-595 at the Annual Meeting of the American Association for Cancer Research
6. Sunesis Pharmaceuticals to Present at the Rodman & Renshaw 5th Annual Global Healthcare Conference
7. Sunesis Pharmaceuticals to Present at the Collins Stewart Fourth Annual Growth Conference
8. Sunesis Pharmaceuticals Announces Up To $43.5 Million Financing
9. Sunesis Reports Financial Results for the First Quarter 2009
10. HHS Announces $75 Million in Supplemental Funding to States for Pandemic Flu Preparedness
11. CRC Health Group Announces Acquisition of Bayside Marin Recovery Center, San Rafael
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/7/2015)... ... July 07, 2015 , ... The United States Centers for Disease Control ... , and the Multicultural AIDS Coalition $3.78 million for a five-year HIV ... with men (MSM) and transgender women, the groups at highest risk of HIV ...
(Date:7/7/2015)... ... July 07, 2015 , ... Quadrino Law Group is pleased to announce ... New York 11747. The new facility is a state of the art building, ... Richard Quadrino, the firm's CEO and founder, said, "We are pleased to service our ...
(Date:7/7/2015)... ... July 07, 2015 , ... ... technologies and development solutions for drugs, biologics and consumer health products, today ... to access its antibody combination therapy (ACT) technology platform. The platform has ...
(Date:7/7/2015)... ... July 07, 2015 , ... Summer is a great time ... so Amica Insurance is sharing some safety tips. , Jean Tapley, senior wellness coordinator ... Leisure activities/sports, , Start slowly. Going from no activity to ...
(Date:7/7/2015)... ... July 07, 2015 , ... On Saturday, May 16th, 2015, the ... Manistee Golf and Country Club. Best Drug Rehabilitation staff members were delighted to join ... underprivileged children. Kiwanis International, the parent of the Manistee Kiwanis Club, is a global ...
Breaking Medicine News(10 mins):Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 2Health News:CDC Awards Fenway Health, AIDS Action, Multicultural AIDS Coalition $3.78m For ‘Getting To Zero’ HIV Prevention Partnership 3Health News:Catalent Biologics Adds New Technology Platform to Enable Antibody Combination Therapies 2Health News:Amica Insurance Has 7 Summer Safety Tips 2Health News:Best Drug Rehabilitation Team Participates in Kiwanis Club Golf Outing Fundraiser 2
... researchers older people have a less chance of surviving lung ... in time. On an average older people are more susceptible ... a ventilator.// What's not been clear is whether they do ... new study suggests that age is indeed a factor in ...
... of serotonin-raising drugs like antidepressants and slimming pills in ... of durgs is by increasing the levels of serotonin, ... body.// Examples include diet pills, anti-migraine drugs and some ... Health welfare hospital, warn of the potential dangers of ...
... patients on long-term non-steroidal anti-inflammatory drug (NSAID) treatment ... can substantially reduce the risk of ulcer formation.// ... cent of H.pylori infections and reduced the six-month ... the control group to 12 per cent in ...
... women whose jobs require too much exposure to solvents ... have chilren with defective eyesight. Head researcher Dr. Gideon ... of Occupational health. ,They found that poor ... mothers were frequently exposed to organic solvents at work ...
... School researchers have discovered nearly all the genes responsible ... blinding diseases.Macular degeneration affects 20 per cent of people ... photoreceptor genes expressed int he retinal cells, which was ... for preserving and restoring the vision of those affected.// ...
... People who suffer from asthma, particularly women, may have ... period of 30 years, researchers studied almost 100,000 patients ... of the patients showed any signs of cancer at ... second year after asthma diagnosis until the last day ...
Cached Medicine News:Health News:Genes for Vision discovered 2
(Date:7/7/2015)... , July 7, 2015   ICD-10 Charts ... months of development, it has officially launched its ... Charts Training Academy and the new 4 Step ... well as all other ICD-10 Charts resources and ... in America, completely free-of-charge.  With the release of ...
(Date:7/7/2015)... 2015 Research and ... the "Elemental Analysis Market by Type (Organic, ... Application (Life Sciences, Food and Beverage Testing, Environment ... report to their offering. The ... types, technologies, and applications. By type, the market ...
(Date:7/7/2015)... and FREMONT, Calif. , July 7, ... South Korea and Velos, Inc. have entered into ... eResearch for cancer research nationally throughout South Korea ... The recent agreement signing was accompanied by a two day ... , South Korea.  National Cancer Center President ...
Breaking Medicine Technology:ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 2ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 3ICD-10 Charts Releases Revolutionary Free Solution for Complete ICD-10 Preparation 4Elemental Analysis (Organic, Inorganic) Market 2015 - Analysis & Global Forecasts to 2020 2National Cancer Center of South Korea and Velos Sign Long-Term Velos eResearch Agreement 2National Cancer Center of South Korea and Velos Sign Long-Term Velos eResearch Agreement 3
... Oct. 6 According to Millennium Research Group ... intelligence, growth in the $2 billion US cardiac ... the expanded approval of Boston Scientific,s chronic resynchronization ... I and II patients. The New ...
... Oct. 6 e-MDs, an industry leader in ... (EHRs) and practice management (PM) solutions,  congratulates  the ... Family Medicine of Fort Collins, CO, for their ... of Excellence recipients.  The Healthcare Information and Management ...
Cached Medicine Technology:Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators 2Positive Results From the MADIT-CRT Trial Support the Expanding Approval of Cardiac Resynchronization Therapy Defibrillators 3e-MDs Clients Win HIMSS Davies Awards of Excellence 2e-MDs Clients Win HIMSS Davies Awards of Excellence 3e-MDs Clients Win HIMSS Davies Awards of Excellence 4
The 920M PLUS handheld pulseoximeter provides on-the-spot bloodoximetry and heart rate readings....
Rad-5 signal extraction pulse oximeter™...
... 3100 is a small, lightweight ... worn comfortably on the patients ... activities and for overnight studies, ... WristOx is intended to give ...
The pocket-size Invacare Digit finger pulse oximeter is a convenient and economical solution to fast, reliable SpO2, pulse rate and pulse strength measurements. Its compact size is ideal for home use...
Medicine Products: